| Shea Michelle Harrel, | |
|
1616 N 7 Hwy, Blue Springs, MO 64014-1936 | |
| (816) 228-6848 | |
| (816) 228-6953 |
| Full Name | Shea Michelle Harrel |
|---|---|
| Gender | Female |
| Speciality | Pharmacist |
| Location | 1616 N 7 Hwy, Blue Springs, Missouri |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1376147330 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 183500000X | Pharmacist | 2000165335 (Missouri) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shea Michelle Harrel, 1616 N 7 Hwy, Blue Springs, MO 64014-1936 Ph: (816) 228-6848 | Shea Michelle Harrel, 1616 N 7 Hwy, Blue Springs, MO 64014-1936 Ph: (816) 228-6848 |
News Archive
The New York Times reports on a new approach to getting patients to take their medications consistently: financial incentives. "One-third to one-half of all patients do not take medication as prescribed, and up to one-quarter never fill prescriptions at all, experts say. Such lapses fuel more than $100 billion dollars in health costs annually because those patients often get sicker. Now, a controversial, and seemingly counterintuitive, effort to tackle the problem is gaining ground: paying people money to take medicine or to comply with prescribed treatment."
Covidien plc today reported results for the third quarter of fiscal 2010 (April - June 2010). Third-quarter net sales of $2.56 billion increased 2% from the $2.52 billion reported a year ago, with foreign exchange rate movement having no impact on the quarterly sales growth rate.
Athersys, Inc. announced today positive results from its phase I clinical trial of MultiStem®, its allogeneic cell therapy product, administered to individuals following acute myocardial infarction (AMI), more commonly referred to as a heart attack. The study results, based on four months of post-treatment patient data, demonstrate that MultiStem was well tolerated at all dose levels and also suggest improvement in heart function in treated patients.
Trovagene, Inc., a developer of cell-free molecular diagnostics, today announced the launch of a study that aims to determine utility of the Company's Precision Cancer Monitoring (PCM) technology for predicting response to treatment in advanced melanoma patients receiving one or a combination of the novel immunotherapy agents Yervoy (ipilumumab), a CTLA-4 inhibitor, and Opdivo (nivolumab), a PD-1 inhibitor.
Myriad Genetics, Inc. today announced new clinical studies on its myChoice HRD companion diagnostic test at the 2015 American Society of Clinical Oncology annual meeting being held in Chicago, Ill.
› Verified 3 days ago
Dr. Gregory Adam Wilson, PHARM D Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1701 Nw 7 Hwy, Blue Springs, MO 64015 Phone: 816-220-3620 | |
Dr. Ashley L Copes, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3200 S 7 Hwy, Blue Springs, MO 64014 Phone: 816-220-8455 Fax: 816-220-8807 | |
Mr. John R Dillon, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 3200 S 7 Hwy, Blue Springs, MO 64014 Phone: 816-220-8455 Fax: 816-220-8807 | |
Michael Allen Hefley, PHARMACIST Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 205 R.d. Mize Road, Marrs Pharmacy, Blue Springs, MO 64014 Phone: 816-229-7755 Fax: 816-229-1052 | |
Kim Pham, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1701 Nw State Route 7, Blue Springs, MO 64014 Phone: 816-220-3620 | |
Dr. Susan Fields, PHARMD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1700 N 7 Hwy, Blue Springs, MO 64014 Phone: 816-427-9023 | |
Kyle Temple, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 600 Ne Coronado Dr, Blue Springs, MO 64014 Phone: 816-228-2801 |